Nuvo Pharmaceuticals Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported revenue was CAD 68.91 million compared to CAD 73.78 million a year ago. Net loss was CAD 32.21 million compared to CAD 4.13 million a year ago.

Basic loss per share from continuing operations was CAD 2.83 compared to CAD 0.36 a year ago. Diluted loss per share from continuing operations was CAD 2.83 compared to CAD 0.36 a year ago.